Aims The central antihypertensive drug moxonidine lowers blood pressure (BP) through stimulating an imidazoline receptor within the rostral ventrolateral medulla (RVLM). Nitric oxide (NO) generated by the inducible NO synthase (iNOS) in the RVLM has been suggested to be involved in tonic sympathetic inhibition. The aim of this study was to determine the role of NO generated by iNOS in mediating moxonidine-induced cardiovascular inhibition in rats.
Introduction
The centrally acting drugs such as clonidine, rilmenidine, and moxonidine lower blood pressure (BP) and inhibit sympathetic outflow through actions at I 1 -imidazoline receptors (I 1 R) and/or a 2 -adrenoceptors (a 2 ARs) within the central nervous system. [1] [2] [3] The rostral ventrolateral medulla (RVLM), a key region for the control of sympathetic outflow and BP, has been widely accepted to be a target area for centrally acting drugs. [3] [4] [5] However, the hypotension of centrally acting drugs is not fully understood. Interestingly, it is reported that the effect of centrally acting drugs is closely related to the nitric oxide (NO) mechanism in the central nervous system. [6] [7] [8] [9] [10] For example, clonidine significantly stimulates the release of NO in the brainstem. 6 Pre-treatment with intracerebroventricular (ICV) infusion of the non-selective NO synthase (NOS) inhibitor N G -nitro-Larginine-methyl ester (L-NAME) significantly attenuates the cardiovascular inhibition evoked by clonidine or moxonidine. 6, 7 In an acute hypertensive model, pre-treatment with intravenous L-NAME also attenuates moxonidinerelated hypotension. 8 Therefore, it appears that the cardiovascular inhibition of centrally acting drugs is dependent on the central NO mechanism.
It is well known that NO, acting as a central neurotransmitter, plays an important role in central cardiovascular regulation. 11, 12 NO is produced from L-arginine through NOS including neural, inducible, and endothelial synthase (nNOS, iNOS, and eNOS). 13 All three types of NOS have been demonstrated to be expressed in the important cardiovascular centres such as the RVLM and the nucleus tractus solitarius (NTS).
14, 15 The role of NO in cardiovascular † The first two authors contributed equally to this work.
regulation has been reported to be excitatory or inhibitory. [16] [17] [18] [19] [20] The pathophysiological consequences of endogenous NO derived from differential NOS in the RVLM are not in complete agreement. [21] [22] [23] It is generally accepted that the activity of iNOS in the brain is low in the normal state but it is principally induced by macrophage in response to inflammatory stimuli. 24 In the RVLM, however, it is suggested that the blockade of endogenous NO derived from iNOS elicits an increase in BP and sympathetic activity in normal rat. 21 The inhibitory effect of endogenous NO derived from iNOS on the tonic cardiovascular activity in the RVLM is associated with the release of inhibitory amino acid. 21, 25 Moreover, it is reported that iNOS expression in the RVLM is decreased in hypertensive rats, suggesting contribution of downregulated iNOS in the RVLM to sympathoexcitation in hypertension. 22, 26 On the basis of the above evidence and the relationship between central mechanisms and NO, we hypothesize that the endogenous NO generated selectively from iNOS contributes to the cardiovascular inhibition of centrally acting drugs. In the current experiment, we determined the effects of the blockade of endogenous NO derived from iNOS on the cardiovascular response of the centrally acting drug moxonidine, a selective I 1 R agonist, 3 in anaesthetized rats. Furthermore, using molecular biology techniques (immunofluoresence and western blot), we examined the effects of chronic administration of moxonidine on the expression of iNOS protein in the RVLM and the NTS.
Methods

Animals
Male Sprague-Dawley rats weighing between 300 and 350 g were supplied by Sino-British SIPPR/BK Laboratory Animal Ltd for these experiments. All studies conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the Institutional Care and Use Committee of the Second Military Medical University. The acute experiments, including the general surgical procedures, ICV injection, and RVLM microinjection, were carried out as described previously.
27,28
General surgical procedures
Briefly, rats were anaesthetized with urethane (800 mg/kg i.p.) and a-chloralose (40 mg/kg i.p.), and the trachea was cannulated to facilitate mechanical respiration. Ventilation parameters were adjusted to maintain PaO 2 at 100 mmHg and PaCO 2 below 40 mmHg. The right common carotid artery was catheterized for BP measurement. The mean arterial pressure (MAP) and heart rate (HR) were derived from the BP pulse. The jugular and femoral veins were cannulated for supplemental anaesthesia (a-chloralose, 10 mg/kg) and neuromuscular blockade (gallamine triethiodide, 10 mg/kg initially, supplemented with 4 mg/kg as needed). Body temperature was kept at 378C.
Acute and chronic ICV infusion
The procedure for acute or chronic ICV injection was similar as described previously. 29, 30 The rats receiving acute ICV injections were subjected to a limited craniotomy. ICV injection was performed using a 10 mL syringe (Hamilton, Reno, NV, USA). On the basis of the rat atlas of Paxinos and Watson (1998) , the coordinates for the left lateral cerebral ventricles were 1.0 mm posterior to Bregma, 1.5 mm lateral to midline, and 4.5 mm below the outer surface of the skull. The volume for ICV injection was 5 mL 31 and made over a period of 1 min. The maximum effect of ICV injection of moxonidine on BP and HR was detected 20 min after pretreatment with vehicle or three doses of S-methylisothiourea (SMT), a potent selective inhibitor of iNOS. 25, 32 The chemicals including moxonidine, SMT, and glutamate for ICV injections or following RVLM microinjections were obtained from Sigma and dissolved in artificial cerebrospinal fluid (aCSF, pH 7.4). The injection (ICV or RVLM) doses of moxonidine and SMT were similar to previous studies. 7, 21, 28 At the end of each experiment, the brain was taken from the skull and the injection site was further detected. The injection sites for ICV were verified to be in correct position.
The rats receiving chronic ICV injections were anaesthetized by a compound of ketamine-diazepam (75 and 5 mg/kg, respectively, i.p.). Stainless steel 28 gauge cannula were positioned in the left lateral ventricle and fixed in position by dental cement attached to three stainless steel screws driven into the skull. A stainless steel obdurator, which protruded 0.5 mm beyond the guide cannula, was inserted to maintain cannula patency. Animals were housed singly thereafter and handled daily so that they would become familiar with the manipulations of the experiment. After 1 week recovery, rats were divided into two groups and given a daily ICV injection of moxonidine (20 nmol in 5 mL) or aCSF (5 mL) for 2 weeks. Before the rats were euthanized for protein expression measurement, they were anaesthetized and the haemodynamic parameters were recorded for 30 min, which were collected for further statistical analysis.
RVLM microinjection
The rat was placed in a stereotaxic frame, and the dorsal surface of the medulla was surgically exposed. Microinjections were made from a four-barrel micropipette (20-50 mm diameter). The coordinates for RVLM were 2.0-2.5 mm rostral and 1.8-2.1 mm lateral to calamus scriptorius and 2.8-3.2 mm ventral to the dorsal surface of the medulla. The injection was made over a period of 5-10 s and the injection volume (100 nL) was carefully measured by observing the movement of the fluid meniscus along a reticule in a microscope. The RVLM was chemically identified by L-glutamate (1 nmol) microinjection. The changes in BP, HR, and renal sympathetic nerve activity (RSNA) evoked by RVLM (5 nmol in 100 nL) or intravenous injection of moxonidine (50 mg/kg in 0.2 mL normal saline) were collected 10 min after treatment with vehicle (aCSF) or SMT (20 and 200 pmol) . At the end of each experiment, 100 nL of 2% pontamine sky blue solution was injected into the RVLM to mark the site. The injection sites in the study were confirmed to be located within the RVLM area, which are similar to those described previously.
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Recording of RSNA
The RSNA was recorded as described previously. 33 The renal sympathetic nerves were exposed and placed on a pair of recording electrodes. The distal terminal of the renal nerve was cut to avoid afferent activity. The RSNA was amplified and recorded. Baseline RSNA was taken as 100% from the absolute value after the noise level (measured by intravenous hexamethonium) was subtracted.
Immunohistochemistry
The procedure for immunofluorescent staining was described previously by Guo et al. 34 Chronic (2 weeks) infusion (ICV) of aCSF (5 mL/day) or moxonidine (20 nmol/day in 5 mL) was carried out in two rat groups. Before the rats were euthanized by overdose of pentobarbitone sodium, baseline BP and HR were measured. The rats were euthanized and perfused through the aorta with 0.9% NaCl solution and 4% paraformaldehyde in 0.1 mol/L phosphate buffer, pH 7.4. The brains were removed and refixed in 4% paraformaldehyde in 0.1 mol/L phosphate buffer, pH 7.4, overnight. The brain blocks were then transferred to 20% sucrose in phosphate-buffered saline (PBS) and kept in the solution until they sank to the bottom.
Then, the brain blocks were rapidly frozen. Sections of 20 mm thickness were cut in a cryostat and floated in PBS. The floating sections were washed three times 5 min in 0.01 mol/L, pH 7.2, PBS. The sections were pre-incubated in 10% normal horse serum (NHS), 0.2% Triton X-100 in PBS for 30 min, followed by incubation with rabbit polyclonal antiserum against iNOS (Santa Cruz, sc-650) or nNOS (Santa Cruz, sc-648) diluted 1:100 in antibody dilution solution (10% NHS, 0.2% Triton X-100, and 0.4% sodium azide in PBS), overnight at room temperature. Subsequently, the sections were incubated with Alexa Fluor 594 donkey anti-rabbit IgG (Invitrogen, A21207) diluted 1:200 in antibody dilution solution for 2 h at room temperature. All the incubations and reactions were separated by three times 5 min washes in PBS. Finally, the sections were then mounted on slides, dehydrated and cleared in xylene, and embedded. Images were taken with the Nikon digital camera DXM1200 (Nikon) attached to a Nikon Eclipse E600 microscope (Nikon, Japan). According to the rat atlas, 35 the intensity of iNOS or nNOS immunofluorescent staining in the target area RVLM or the NTS was quantified using Openlab 4.0.2 (Improvision, Lexington, MA, USA). For each animal, the integrated intensities of the target areas from both sides of two sections were averaged for subsequent analysis. The integrated intensity of the target areas in the control group (ICV infusion of aCSF) was normalized as 100.
Western blot analysis
After the measurement of haemodynamic parameters, the two groups of rats receiving infusion (ICV, 2 weeks) of vehicle (aCSF 5 mL/day) or moxonidine (20 nmol/day) were euthanized and the brains were removed for western blot analysis. The NTS and RVLM tissue were punched from 100 mm coronal sections of brainstem according to the rat atlas. 35 The protein concentration was measured and loaded onto a 7.5% SDS-PAGE gel and then transferred to a polyvinylidene fluoride membrane. One lane on the right contained a molecular weight marker, which provides a visual check of transfer efficiency and marks band position for target protein.
The membrane was probed with primary (iNOS rabbit anti-mouse, Santa Cruz, sc-650, 1:1000) and secondary antibodies (1:5000). The protein bands were visually detected and analysed. The levels of target proteins were normalized to GAPDH, which served as a loading control.
Statistical analysis
All values are expressed as mean + SEM. In the acute experiments, the averaged value of MAP, HR, or RSNA was calculated every 3 min after the injection of a test agent or vehicle. The difference between pre-and post-treatment was detected by Student's t-test (paired). Statistical comparisons between different groups were made by the repeated measures one-way ANOVA followed by Student-Newman-Keuls post hoc test. All analyses were performed by software (SigmaStat 3.5). A value of P , 0.05 was considered statistically significant. Table 1 and were not different among the experimental groups. Figure 1A shows representative original traces of the BP and HR responses to ICV-injected moxonidine (20 nmol) 20 min after pre-treatment with vehicle (aCSF) or SMT (100 nmol). ICV injection of moxonidine (20 nmol in 5 mL) following aCSF injection significantly (P , 0.05) reduced MAP (222 + 3 mmHg) and HR (258 + 13 beats/min (b.p.m.)]. In general, the maximal effects of ICV moxonidine were reached within 30 min and then gradually returned to control levels (.60 min). However, the hypotensive and bradycardic effects of ICV moxonidine (20 nmol) were dose-dependently attenuated 20 min after ICV injection of SMT (1, 10, and 100 nmol). The peak changes in MAP and HR evoked by ICV moxonidine after pretreatment with SMT are shown in Figure 1B . We also noted that the baseline BP was significantly (P , 0.05) increased by 8.5 + 1.2 mmHg compared with control following ICV injection of the highest dose (100 nmol) of SMT, but they were almost back to control levels before moxonidine was subsequently injected. Figure 2A shows the BP, HR, and RSNA responses to microinjection of moxonidine (5 nmol) following prior injection of aCSF (100 nL) and SMT (200 pmol) unilaterally into the RVLM. The baseline BP and HR in several groups are shown in Table 1 . At least 30 min before moxonidine or SMT injection, a transient pressor response to injected glutamate (1 nmol) was used to chemically identify the RVLM injection site. Unilateral injection of the high dose of SMT produced a transient increase in BP (7.8 + 1.0 mmHg, P , 0.05) and RSNA (42.5 + 5.9%, P , 0.05) compared with pre-injection levels. From Figure 2B , it can be seen that SMT treatments (20 and 200 pmol) significantly (P , 0.05) attenuated the decrease in MAP, HR, and RSNA response to RVLM injection of moxonidine in a dose-dependent manner.
RVLM microinjection of moxonidine
Intravenous injection of moxonidine
The effect of blockade of iNOS within the RVLM on the depressor action of systemic moxonidine was further observed in 11 rats. The baseline BP and HR are shown in Table 1 . Intravenous injection of moxonidine (50 mg/kg) following pre-treatment with vehicle produced a longterm decrease in BP and HR. In most cases, the 
Data are expressed as mean + SE. n, the number of the rats in each group; Mox, moxonidine. moxonidine-induced hypotension did not reach the maximum level within 1 h and was not restored to the preinjection level within 2 h. Figure 3A shows the original recording of BP in response to intravenously injected moxonidine (50 mg/kg) 10 min after pre-treated aCSF or SMT (200 pmol) in the bilateral RVLM. A significant (P , 0.05) increase in BP (12.2 + 1.7 mmHg) and HR (42.5 + 5.4 b.p.m.) was observed after bilateral microinjection of SMT (200 pmol) into the RVLM. We found that pre-treatment with SMT significantly (P , 0.05) attenuated the depressor action induced by intravenous moxonidine without affecting the decrease in HR by intravenous moxonidine (Figure 3B and C).
The protein expression of iNOS in the RVLM
Immunohistochemistry
Before the rats were euthanized, baseline BP and HR were measured under anaesthesia. Both baseline BP (aCSF: 114 + 4 mmHg; moxonidine: 91 + 4 mmHg) and HR (aCSF: 406 + 8 b.p.m.; moxonidine: 342 + 8 b.p.m.) were significantly (P , 0.05) reduced after chronic infusion of moxonidine (20 nmol/day for 2 weeks) compared with aCSF infusion. Figure 4A and B illustrates typical images of the RVLM and NTS with immunofluorescent labelling for iNOS or nNOS in rats receiving chronic infusion of aCSF or moxonidine. The protein expression of iNOS clearly appeared in the RVLM from the rat that received infusion of moxonidine, whereas in rats that received infusion of aCSF, the presence of immunofluorescent labelling of iNOS was markedly (P , 0.05) less in the RVLM ( Figure 4C ). This figure also shows that there was no measurable difference (P . 0.05) in the iNOS protein labelling in the NTS from rats between aCSF and moxonidine groups. Moreover, immunofluorescent labelling for nNOS in the RVLM or NTS was not changed in the moxonidine group compared with the aCSF infusion group ( Figure 4B ). 
Western blot analysis
Another 10 rats were euthanized for western blot analysis after chronic ICV infusion (2 weeks) of moxonidine or aCSF. Baseline BP (aCSF: 109+3 mmHg; moxonidine: 93+3 mmHg) and HR (aCSF: 394 + 13 b.p.m.; moxonidine: 340+10 b.p.m.) were significantly (P , 0.05) decreased in the moxonidine group compared with the aCSF group. Figure 5 shows that the protein expression of iNOS in the RVLM was significantly upregulated (1.5-fold) in the moxonidine infusion group compared with the aCSF group. In the NTS, however, iNOS protein expression was not different between groups. These data suggest that iNOS protein expression is selectively upregulated in the RVLM, following moxonidine administration.
Discussion
The results from the present study demonstrate that: (i) acute blockade of endogenous NO derived from iNOS in the central nervous system (RVLM) effectively prevents the hypotensive and sympathoinhibitory effects evoked by the centrally acting drug moxonidine; and (ii) chronic administration of moxonidine upregulates the protein expression of iNOS in the RVLM. Together, the important evidence obtained from this work supports the hypothesis that cardiovascular inhibition of the centrally acting drug moxonidine is dependent, at least partially, on the release of NO derived from iNOS in the RVLM.
In the present study, we first observed the effect of the iNOS inhibitor SMT on cardiovascular responses to central administration of moxonidine. In fact, SMT is a non-selective inhibitor of NOS with relative selectivity towards iNOS and is recognized as a potent inhibitor of iNOS. SMT is reported to be four times more selective for iNOS when compared with nNOS and much more selective when compared with eNOS. 32, 36, 37 Because we did not test the specificity of SMT to iNOS in the present study, we do not completely exclude the possibility that SMT also affects the activity of n/eNOS in this study. However, on the basis of previous studies in the RVLM, 21 ,38 a similar dose of SMT was believed to be specific to iNOS activity. It is further reported that SMT in the RVLM can effectively prevent the cardiovascular response induced by specific gene transfer of iNOS into the RVLM. 39 Therefore, we believe that SMT is capable of effectively inhibiting iNOS activity in the present.
We also confirmed that central (ICV and RVLM) injection of SMT produced a cardiovascular excitation, as described previously. 21 Importantly, our acute experiments show that ICV or RVLM injection of the iNOS inhibitor SMT dosedependently attenuates the moxonidine-induced hypotension and sympathoinhibition. These data strongly support the idea that the effect of moxonidine is dependent on the release of NO derived from iNOS in the brain. Because the endogenous NO derived from iNOS in the RVLM plays an important role in mediating tonic cardiovascular inhibition, as described presently and previously, 21 it is logical to assume that the effect of moxonidine is closely related to the enhanced activity of iNOS in the RVLM. In our molecular experiments relating to this work, we further determined that the expression of iNOS protein in the RVLM is upregulated following chronic administration of moxonidine.
The current data from immunofluorescence and western blotting analysis demonstrated that chronic administration (2 weeks for ICV) of moxonidine upregulated the protein expression of iNOS in the RVLM but not in the NTS. A significant fall in BP following 2 week infusion of moxonidine suggests the efficacy of the dose of moxonidine. These data suggest that the upregulation of iNOS expression induced by moxonidine is selectively located within the RVLM. Moreover, we demonstrated that the depressor action of systemic moxonidine was effectively attenuated by pre-treated SMT within the RVLM, suggesting the importance of the activity of iNOS in the RVLM in mediating the effect of systemic moxonidine. Surprisingly, we found that the decrease in HR induced by systemic moxonidine was not significantly affected by SMT treatment in the RVLM. The regions for HR control are mainly located in vagal centres (e.g. nucleus ambiguus and the dorsal motor nucleus of the vagal nerve). It is reported that the acting receptors of centrally acting drugs are expressed in the vagal centres, and the centrally acting drug clonidine and moxonidine also modulate the parasympathetic activity. [40] [41] [42] Therefore, the possibility is that iNOS inhibition at the RVLM level does not attenuate the effect of intravenous moxonidine on HR at the level of vagal centres.
On the basis of the current data, we suggest that ICV or intravenous application of moxonidine upregulates the iNOS activity (expression) and thereby stimulates the release of endogenous NO in the RVLM. The previous data suggest that the endogenous NO derived from iNOS in the RVLM produces a decrease in sympathetic outflow and BP. Therefore, we suggest that the enhancement of the endogenous NO release derived from iNOS in the RVLM may be responsible for hypotension and sympathoinhibition of moxonidine. Notably, since the moxonidine effect was not completely abolished by pre-treatment with iNOS inhibitor in this study, we think that NO may not be the sole mechanism responsible for the effect of moxonidine. It is suggested that the effect of centrally acting agents is related to the release of several neurotransmitters such as excitatory amino acids and norepinephrine in the RVLM. 28, [43] [44] [45] [46] Moreover, it is not clear whether alteration in the release of these neurotransmitters induced by centrally acting agents is related to the NO mechanism.
We also found that the expression of iNOS protein in the NTS was not significantly altered after chronic moxonidine, supporting the possibility that the effect of moxonidine does not result from an NO mechanism in the NTS. It is well known that the NTS plays a crucial role in cardiovascular regulation. 47 Moreover, it has been demonstrated that NTS NO is involved in mediating cardiovascular regulation. [48] [49] [50] However, it appears that the NTS may be not an important region for mediating the effect of centrally acting drugs. 2, 50, 51 We speculate that moxonidine does not modify the activity of NOS, at least iNOS, in the NTS. A previous study 6 shows that clonidine triggers the release of NO in the NTS. The possibility is that clonidine acts both I 1 R and a 2 AR. In the NTS, only a 2 AR is believed to be involved in mediating effects of clonidine. 52 However, the selective I 1 R agonist rilmenidine or moxonidine injected into the NTS has little effect on cardiovascular activity. 2, 51 In contrast, the RVLM I 1 R has been accepted to be involved in mediating the effect of centrally acting drugs. 1, 5, 51, 53 Therefore, it is possible that the release of NO derived from iNOS induced by moxonidine requires I 1 R activation in the RVLM.
Certain study limitations do exist. First, it is not clear which acting receptor (I 1 R or a 2 AR) in the RVLM mediates the interaction between NO and moxonidine, because selective antagonists for these receptors have not been used in the present study. There is a continuing and yet unresolved debate regarding the contribution of I 1 R, a 2 AR, or both, on the effects of centrally acting drugs. 4 It has been demonstrated that the effect of centrally acting drugs such as clonidine and moxonidine in the RVLM is completely abolished by an I 1 R antagonist but not by an a 2 AR antagonist. 1, 5 It is likely that only I 1 R in the RVLM contributes to the effect of centrally acting drugs. Therefore, we think that an I 1 R mechanism in the RVLM may mediate the interaction between NO and moxonidine in the present study.
Second, it is suggested that the tonic sympathetic outflow mediated by the NO mechanism in the RVLM may be dependent on the balance between iNOS and nNOS. 21 Therefore, the cardiovascular inhibition by centrally acting drugs may result from downregulated nNOS activity, or upregulated iNOS activity, or both. A previous study 54 has demonstrated that clonidine can selectively inhibit nNOS activity and enhance iNOS activity in glioma cells. However, our data also suggested that, following chronic administration of moxonidine, nNOS protein expression in the RVLM was not altered ( Figure 4B ). Therefore, it is possible that the enhancement of iNOS in the RVLM is the major mechanism responsible for the effect of moxonidine.
Finally, the current data did not address the question of how the interaction between upregulated iNOS and the effect of moxonidine takes place. It is possible that centrally acting drugs regulate gene transcription of iNOS via intracellular signal pathways. 54 It is reported that the intracellular signal transduction of I 1 R stimulation is closely related to signal transduction pathways such as protein kinase C (PKC) or mitogen-activated protein kinase (MAPK). [55] [56] [57] Importantly, the activation of the signalling component PKC or MAPK plays an important role in enhancing the transcriptional activation of the iNOS gene. 58, 59 More recently, Su et al. 60 reported that the centrally acting drug clonidine significantly enhances the nuclear translocation of nuclear factor kappa B (NF-kB) and increases NF-kB-DNA-binding activity, which plays a crucial role of NF-kB in mediating clonidine-induced enhancement of iNOS expression. Therefore, these studies provide evidence to support a possibility that the intracellular PKC or MAPK signal pathway is involved in processing the interaction between I 1 R activation and enhancement of iNOS expression. The specific intracellular link between iNOS activity and moxonidine needs to be further defined. In summary, the present study demonstrates that central blockade of the endogenous release of NO derived from iNOS prevents the cardiovascular effects of moxonidine. Chronic administration of moxonidine upregulates the protein expression of iNOS in the RVLM. However, because of the current data obtained from the normotensive and anaesthetized rats, it is not known whether the same relationship exists in hypertension or a conscious model. NOS activity in the RVLM is altered in hypertension, and therefore it may be more significant to determine the relationship between the NO mechanism and the effects of imidazoline-like drugs in the hypertensive or conscious animal.
